When was JHL Biotech founded?

JHL Biotech was founded in 2012.

Where is JHL Biotech located?

JHL Biotech is headquartered in Hsinchu, Taiwan.

How many employees does JHL Biotech have?

As of May 31, 2026, the latest employee count at JHL Biotech is 60.

Is JHL Biotech a funded company?

JHL Biotech is a funded company, having raised a total of $187M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round.

When was the latest funding round of JHL Biotech?

JHL Biotech's latest funding was a $***** Series D round on Oct 03, 2018, with participation from 1 investor.

Where does JHL Biotech rank among its competitors?

JHL Biotech ranks 4th amongst 44 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Kashiv BioSciences, which secured $72.3M in Dec, 2025.

Who are the top competitors of JHL Biotech?

JHL Biotech's top competitors include Bionova Scientific, Just Biotherapeutics and Avid Bioservices. Among them, Kashiv BioSciences secured the most recent funding round in December, 2025.

JHL Biotech - 2026 Company Profile, Funding & Competitors

JHL Biotech is a series D company based in Hsinchu (Taiwan), founded in 2012. It operates as a CDMO solutions to companies developing and commercializing affordable biologics. JHL Biotech has raised $187M in funding. The company has 44 active competitors, including 4 funded and 14 that have exited. Its top competitors include companies like Bionova Scientific, Just Biotherapeutics and Avid Bioservices.

Company Details

JHL Biotech provides contract manufacturing solutions to companies developing and commercialising affordable biologic medicines in Asia. The company offers cell line cloning, process development, and manufacturing capabilities and services to emerging and established biopharmaceutical companies. Its services include antibody cloning, monoclonal antibody manufacturability and protein engineering, cell line development, master and working cell banks, cell culture process development, purification process development, formulation development, analytical assays, clinical manufacturing, and commercial manufacturing based on mammalian cell lines. The company has strategic development and manufacturing alliances with Selexis, Sanofi, and Aslan Pharmaceuticals, and BeiGene.

Key Metrics

Founded Year

2012

Location

Hsinchu, Taiwan

Stage

Series D

Total Funding

$187M in 6 rounds

Latest Funding Round

Series D, Oct 03, 2018, $*****

Investors

Sanofi & 12 more

Ranked

4^th among 44 active competitors

Employee Count

60 as on May 31, 2026

Similar Companies

Bionova Scientific & 51 more

View JHL Biotech's full profile

JHL Biotech has raised a total funding of $187M over 6 rounds. Its latest funding round was a Series D round on Oct 03, 2018 for $*****. 1 investor participated in its latest round. JHL Biotech has 13 institutional investors.

Here is the list of recent funding rounds of JHL Biotech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 03, 2018	6774777	Series D	2881284	8614511	4146907	5670743
May 30, 2018	3861322	Series D	8663289	9081646	6109967	Milestone Capital
Dec 05, 2016	9253983	Post IPO	7181568	2009831	1674860	Sanofi

Access funding benchmarks and valuations. Sign up today!

View details of JHL Biotech's funding rounds and investors

JHL Biotech's employee count trend

JHL Biotech has 60 employees as of May 26. Here is JHL Biotech's employee count trend over the years:

Uncover JHL Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of JHL Biotech include Bionova Scientific, Just Biotherapeutics and Avid Bioservices. Here is the list of Top 10 competitors of JHL Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Bionova Scientific 2013, Fremont (United States), Acquired	Contract Research and Development company developing mammalian cell culture biologics	$22M	CRG, Great Point Partners	54/100
2nd	Just Biotherapeutics 2014, Seattle (United States), Acquired	Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs	$124M	Lilly Asia Ventures, Temasek & 10 others	53/100
3rd	Avid Bioservices 2002, Orange (United States), Acquired	CDMO focused on drug substance development, analytical, and quality & regulatory compliance services	-	Ranger Investments, Ampersand Capital & 3 others	51/100
4th	JHL Biotech 2012, Hsinchu (Taiwan), Series D	CDMO solutions to companies developing and commercializing affordable biologics	$187M	Sanofi, Kleiner Perkins & 11 others	51/100
5th	Rentschler Biopharma 1927, Laupheim (Germany), Funding Raised	Full-service CDMO for biopharmaceuticals	-	-	50/100
6th	64x Bio 2017, San Francisco (United States), Series A	Developer of cell lines and production technologies for advanced therapies	$59.6M	First Round Capital, Fifty Years & 13 others	48/100
7th	Excellgene 2001, Monthey (Switzerland), Acquired	Provider of service covering value chain from DNA vector to purified protein	-	Kulczyk Investments, BioArk	48/100
8th	Kashiv BioSciences 2010, Piscataway (United States), Acquired	Developer of biosimilar medicines	-	GoldenTree	48/100
9th	ProBioGen AG 1994, Berlin (Germany), Acquired	Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars	-	SudBG, SHS & 2 others	45/100
10th	AGC Biologics 2018, Bothell (United States), Unfunded	CDMO focused on development of mammalian and microbial-based therapeutic proteins	-	European Equity Partners	43/100